Advertisement

Ceftriaxone Sodium Injection

[21 July 2014]

Products Affected - Description

Ceftriaxone sodium injection, Bedford
1 gram vials, 10 count (NDC 55390-0311-10)
2 gram vials, 10 count (NDC 55390-0312-10)
10 gram vials, single count (NDC 55390-0316-01)
 
Ceftriaxone sodium injection, Fresenius Kabi
1 gram vials, 25 count (NDC 63323-0346-10)
2 gram vials, 10 count (NDC 63323-0347-20)
10 gram vials, single count (NDC 63323-0348-61)

Ceftriaxone sodium injection, Hospira
1 gram Add-vantage vials, 10 count (NDC 00409-7333-04)
1 gram vials, 10 count (NDC 00409-7332-01)
2 gram vials, 10 count (NDC 00409-7335-03)
2 gram Add-vantage vials, 10 count (NDC 00409-7336-04)
 
Ceftriaxone sodium injection, Sagent
1 gram vials, 25 count (NDC 25021-0106-10)
10 gram vial, single count (NDC 25021-0108-99)

Ceftriaxone sodium injection, Sandoz
500 mg vials, 10 count (NDC 00781-3207-95)
2 gram vials, 10 count (NDC 00781-3209-95)
10 gram vials, single count (NDC 00781-3210-46)
 
Ceftriaxone sodium injection, West-Ward
1 gram vials, 25 count (NDC 00143-9857-25)
 
Ceftriaxone sodium injection, WG Critical Care
2 gram vials, 25 count (NDC 44567-0702-25)

Reason for the Shortage

  • Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
  • Fresenius Kabi states the reason for the shortage is increased demand. 
  • Hospira states the reason for the shortage is manufacturing delay.
  • Sandoz cannot provide a reason for the shortage.
  • WG Critical Care states the reason for the shortage is increased demand.

Available Products

Ceftriaxone sodium injection, Apotex
250 mg vials, 10 count (NDC 60505-0750-04)
500 mg vials, 10 count (NDC 60505-0751-00)
2 gram vials, 10 count (NDC 60505-0753-04)
10 gram vials, single count (NDC 60505-0679-05)

Ceftriaxone sodium injection, BBraun
1 gram/50 mL premix, 24 count (NDC 00264-3153-11)
2 gram/50 mL premix, 24 count (NDC 00264-3155-11)

Ceftriaxone sodium injection, Baxter
1 gram/50 mL premix, 24 count (NDC 00338-5002-41)
2 gram/50 mL premix, 24 count (NDC 00338-5003-41)

Ceftriaxone sodium injection, Bedford
250 mg vials, 10 count (NDC 55390-0309-10)
500 mg vials, 10 count (NDC 55390-0310-10)
 
Ceftriaxone sodium injection, Fresenius Kabi
250 mg vials, 25 count (NDC 63323-0344-10)
500 mg vials, 25 count (NDC 63323-0345-10)

Ceftriaxone sodium injection, Hospira
250 mg vials, 10 count (NDC 00409-7337-01)
500 mg vials, 10 count (NDC 00409-7338-01)
10 gram vials, single count (NDC 00409-7334-10)

Ceftriaxone sodium injection, Lupin
250 mg vials, 10 count (NDC 68180-0611-10)
500 mg vials, 10 count (NDC 68180-0622-10)
1 gram vials, 10 count (NDC 68180-0633-10)
2 gram vials, 10 count (NDC 68180-0644-10)

Ceftriaxone sodium injection, Sagent
500 mg vials, 25 count (NDC 25021-0105-10)
2 gram vials, 25 count (NDC 25021-0107-20)
 
Ceftriaxone sodium injection, Samson Medical Technologies
100 gram SmartPak bulk package (NDC 66288-6100-01)


Ceftriaxone sodium injection, Sandoz
250 mg vials, 10 count (NDC 00781-3206-95)
1 gram vials, 10 count (NDC 00781-3208-95)

Ceftriaxone sodium injection, WG Critical Care
500 mg vials, 25 count (NDC 44567-0700-25)
1 gram vials, 25 count (NDC 44567-0701-25)
10 gram vial, single count (NDC 44567-0703-01)

Ceftriaxone sodium injection, West-Ward
250 mg vials, 25 count (NDC 00143-9859-25)
500 mg vials, 25 count (NDC 00143-9858-25)
2 gram vials, 25 count (NDC 00143-9856-25)

Estimated Resupply Dates

  • Bedford has ceftriaxone 1 gram, 2 gram, and 10 gram vials on back order and the company cannot estimate a release date. Ceftriaxone 500 mg vials are available; however, this product is made at Ben Venue and once supplies are depleted there is no estimated release date for further product.
  • Fresenius has ceftriaxone 2 gram and 10 gram vials on allocation and the product has short-expiration dating. Ceftriaxone 1 gram vials are on back order and the company estimates a release date in late-July. Check wholesaler for availability.
  • Hospira has ceftriaxone 1 gram, 1 gram ADD-Vantage, 2 gram, and 2 gram ADD-Vantage vials on back order and the company estimates a release date in July 2014.
  • Sagent has ceftriaxone 1 gram and 10 gram vials available on allocation.
  • Sandoz has ceftriaxone 500 mg and 2 gram vials on back order and the company estimates a release date in late-July 2014. Ceftriaxone 250 mg gram vials are on back order until late-August 2014. Ceftriaxone 10 gram vials are on back order until mid-August 2014.
  • West-Ward has ceftriaxone 1 gram vials on back order and the company estimates a release date in late-July 2014.
  • WG Critical Care has ceftriaxone 2 gram vials on back order and the company estimates a release date in mid-August 2014. Check your wholesaler for availability.

Related Shortages

Updated

July 21, 2014; July 14, 2014; July 9, 2014; June 17, 2014; June 3, 2014; May 29, 2014; May 14, 2014; May 8, 2014; May 1, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement